5-fluoro-2-isopropoxyaniline | 1019484-18-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-fluoro-2-isopropoxyaniline
• 英文别名: 5-fluoro-2-isopropoxy-phenylamine；5-fluoro-2-propan-2-yloxyaniline
• CAS: 1019484-18-4
• 化学式: C₉H₁₂FNO
• mdl: MFCD11135837
• 分子量: 169.199
• InChiKey: PFIOWSAILYOJEY-UHFFFAOYSA-N

物化性质

• 沸点：
  258.6±20.0 °C(Predicted)
• 密度：
  1.103±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-fluoro-2-isopropoxyaniline 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 N-[(2,5-dimethoxyphenyl)methyl]-2-fluoro-N-(5-fluoro-2-propan-2-yloxyphenyl)acetamide
  参考文献：
  名称：

  Exploration of the structure–activity relationship of the diaryl anilide class of ligands for translocator protein—potential novel positron emitting tomography imaging agents

  摘要：

  A series of novel ligands based on the diaryl anilide (DAA) class of translocator protein (TSPO) ligands was synthesised and evaluated as potential positron emitting tomography (PET) ligands for imaging TPSO in vivo. Fluorine-18 labelling of the molecules was achieved using direct radiolabelling or synthon based labelling approaches. Several of the ligands prepared have promising profiles as potential TSPO PET imaging ligands and will be evaluated further as potential clinical imaging agents. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.093
• 作为产物：
  描述：

  2,5-二氟硝基苯 在 10% Pd/C 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-fluoro-2-isopropoxyaniline
  参考文献：
  名称：

  Exploration of the structure–activity relationship of the diaryl anilide class of ligands for translocator protein—potential novel positron emitting tomography imaging agents

  摘要：

  A series of novel ligands based on the diaryl anilide (DAA) class of translocator protein (TSPO) ligands was synthesised and evaluated as potential positron emitting tomography (PET) ligands for imaging TPSO in vivo. Fluorine-18 labelling of the molecules was achieved using direct radiolabelling or synthon based labelling approaches. Several of the ligands prepared have promising profiles as potential TSPO PET imaging ligands and will be evaluated further as potential clinical imaging agents. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.093

文献信息

• METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
  申请人：JACKSON Paul Francis

  公开号：US20120302573A1

  公开（公告）日：2012-11-29

  This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.

  这项发明涉及预防、治疗或改善由MMP9和/或MMP13介导的综合症、紊乱或疾病的方法，包括向需要的受试者施用本说明书示例部分列出的化合物的有效量，或其形式、组合或药物。治疗和/或预防的疾病包括类风湿关节炎。
• TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
  申请人：WANG Aihua

  公开号：US20120129811A1

  公开（公告）日：2012-05-24

  This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C 1 , C 2 , Z 1 , Z 2 , Q, J, R 1 , and R 3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

  本发明涉及三轮车I及其治疗和预防用途，其中变量C1、C2、Z1、Z2、Q、J、R1和R3在规范中定义。治疗和/或预防的疾病包括类风湿性关节炎。
• PHENYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
  申请人：JACKSON Paul Francis

  公开号：US20120302569A1

  公开（公告）日：2012-11-29

  This invention relates to phenyl thiazole I and its therapeutic and prophylactic uses, wherein the variables R z , Q, J, R 1 , R 3 , R 5 , R 6 , and R 7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

  该发明涉及苯基噻唑I及其治疗和预防用途，其中变量Rz、Q、J、R1、R3、R5、R6和R7在规范中定义。治疗和/或预防的疾病包括类风湿性关节炎。
• [EN] BENZOTHIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION<br/>[FR] INHIBITEURS BENZOLTHIAZOLYLÉS DE L'ACTIVATION DE PRO-MÉTALLOPROTÉINASE DE MATRICE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2012162463A1

  公开（公告）日：2012-11-29

  This invention relates to benzothiazole (formula I) and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, and R6 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

  本发明涉及苯并噻唑（式I）及其治疗和预防用途，其中变量Rz、Q、J、R1、R3、R5和R6在说明书中定义。治疗和/或预防的疾病包括类风湿性关节炎。
• QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION
  申请人：Otsubo Kenji

  公开号：US20100130546A1

  公开（公告）日：2010-05-27

  The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R 1 represents a hydrogen atom, etc.; R 2 represents a hydrogen atom, etc.; R 3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R 4 represents a halogen atom; R 5 represents a hydrogen atom or halogen atom; R 6 represents a hydrogen atom; and R 7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.

  本发明提供了一种喹诺酮化合物，其由通式（1）或其盐所表示，其中R1表示氢原子等；R2表示氢原子等；R3表示苯基，该苯基可以选择性地被一个或多个取代基取代等；R4表示卤素原子；R5表示氢原子或卤素原子；R6表示氢原子；R7表示羟基等。该喹诺酮化合物具有功能改善效果，通过抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而延长首次给药前的期间，抑制神经功能障碍的进展。